Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Other: No treatment given

First Posted Date: 2014-09-03

Last Posted Date: 2015-04-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 704

Registration Number: NCT02230631

Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec/insulin aspart

First Posted Date: 2014-09-03

Last Posted Date: 2018-03-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1029

Registration Number: NCT02230618

Locations: 🇮🇳
Novo Nordisk Investigational Site, Thriruvananthapuram, India

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

Phase 3

Completed

Conditions: Adult Growth Hormone Deficiency
Growth Hormone Disorder

Interventions: Drug: somatropin
Drug: somapacitan
Drug: placebo

First Posted Date: 2014-09-03

Last Posted Date: 2020-11-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 301

Registration Number: NCT02229851

Locations: 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1
Healthy
Diabetes

Interventions: Drug: Insulin 338
Drug: placebo
Drug: insulin glargine

First Posted Date: 2014-08-19

Last Posted Date: 2017-12-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 62

Registration Number: NCT02220296

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: semaglutide

First Posted Date: 2014-08-08

Last Posted Date: 2018-03-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 87

Registration Number: NCT02212067

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Phase 1

Completed

Conditions: Hepatic Impaired
Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide

First Posted Date: 2014-08-07

Last Posted Date: 2017-12-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 44

Registration Number: NCT02210871

Locations: 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide
Drug: DPP-4 inhibitor

First Posted Date: 2014-08-04

Last Posted Date: 2019-01-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 601

Registration Number: NCT02207374

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan

Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors

Phase 1

Completed

Conditions: Obesity
Metabolism and Nutrition Disorder

Interventions: Drug: liraglutide

First Posted Date: 2014-08-04

Last Posted Date: 2016-12-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT02207348

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa

First Posted Date: 2014-08-04

Last Posted Date: 2021-11-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 40

Registration Number: NCT02207218

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Phase 2

Completed

Conditions: Diabetes
Diabetes Mellitus Type 2

Interventions: Drug: Metformin
Drug: Liraglutide
Drug: Placebo
Drug: NNC0090-2746

First Posted Date: 2014-07-31

Last Posted Date: 2020-07-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 108

Registration Number: NCT02205528

Locations: 🇺🇸
Novo Nordisk Investigational Site, Manassas, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy